A device and method are provided which achieve tissue ablation as well as tissue coagulation substantially simultaneously during the treatment of BPH by utilizing at least two wavelengths of light. The device and method improve urinary flow and minimize post-treatment blood loss and edema while maintaining a nearly blood-free operating field during treatment by irradiating substantially simultaneously with at least two different wavelengths of light. According to the present invention, tissue ablation is affected by having one wavelength that is highly absorbed in the prostatic tissue while another less highly absorbed wavelength coagulates surrounding tissues while maintaining minimal thermal damage to surrounding tissue. In a preferred embodiment the highly absorbed wavelength is about 1460 nm and the less absorbed by water but with some significant hemoglobin absorption is about 980 nm. This combination aids the patient by reducing blood loss and edema. It can aid the practitioner, especially where imaging is employed, by maintaining a substantially blood-free area during treatment. The present device and method is used in conjunction with optical fibers including side emitting optical fibers to provide a practical, minimally invasive treatment of enlarged prostates.

Neuberger; Wolfgang

Biolitec Pharma Marketing Ltd

Benign prostatic hyperplasia treatment method and device

The invention relates to novel compounds of the formula I ##STR1##in which R1 to R10 R7 are as defined herein. In one embodiment, these compounds may be used as antihypertensives, for reducing or preventing ischemia-induced damage, as medicaments for surgical intervention for the treatment of ischemias of the nervous system, of stroke and of cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxative, as agent against ectoparasites, to prevent the formation of gallstones, as antiatherosclerotics, agents against late complications of diabetes, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophies and hyperplasias. In another embodiment, the compounds may be inhibitors of the cellular sodium-proton antiporter and influence serum lipoproteins and thus be used for the treatment of atherosclerotic lesions.

Aventis Pharma Deutschland GmbH

Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them

The invention relates to compounds of the formula I ##STR1##in which R1 to R9 are as defined herein. In one embodiment, these compounds may be used as antihypertensives, for reducing or preventing ischemia-induced damage, as medicaments for surgical intervention for the treatment of ischemias of the nervous system, of stroke and of cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxative, as agent against ectoparasites, to prevent the formation of gallstones, as antiatherosclerotics, agents against late complications of diabetes, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophies and hyperplasias. In one embodiment, the compounds may be inhibitors of the cellular sodium-proton antiporter and influence serum lipoproteins and thus be used for the prophylaxis and for the regression of atherosclerotic lesions.

Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

The invention is the compounds 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1.lambda..sup.6 -thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1.lambda..sup.6 -thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i sobutyramide.Compounds of the invention are useful in pharmaceutical compositions for the treatment of migraine, rheumatoid arthritis, asthma, bronchial hyperreactivity, inflammatory bowel disease or for the treatment of disorders including Parkinson's disease, anxiety, depression, pain, headache, Alzheimer's disease, multiple sclerosis, edema, allergic rhinitis, Crohn's disease, ocular injury, ocular inflammatory diseases, psychosis, motion sickness, induced vomiting, emesis, urinary incontinence, psychoimmunologic or psychosomatic disorders, cancer, withdrawal symptoms of addictive drugs from opiates or nicotine, traumatic brain injury or benign prostatic hyperplasia.

hyperplasia/éidéime

Benign prostatic hyperplasia treatment method and device

Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them

Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

Aromatic and heteroaromatic substituted amides

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht